Imagion Biosystems is pleased to announce that it has successfully applied for an Advance/Overseas Finding in relation to its research and development activities for a new superparamagnetic based imaging technology for detection of HER2 breast cancers.
View the announcement.
Corporate Update – IND for MagSense® HER2 Phase 2 Study Immediate Priority
November 14, 2024
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority